Nasus Pharma (NSRX) Change in Account Payables (2024 - 2025)

Nasus Pharma (NSRX) reported Change in Account Payables of $664000.0 for Q2 2025, up 16700.0% quarter-over-quarter from -$4000.0 in Q4 2024.

Nasus Pharma (NSRX) Change in Account Payables (2024 - 2025) Analysis & Trends

Nasus Pharma has reported Change in Account Payables for 2 years, with the latest figure at $664000.0 in Q2 2025.

For the quarter ending Q2 2025, Change in Account Payables changed N/A year-over-year to $664000.0; the trailing twelve-month figure through Jun 2025 stood at $664000.0 (changed N/A YoY), and the FY2025 full-year result was $152000.0, down 76.65% from the prior year.
Change in Account Payables for Q2 2025 stood at $664000.0, up from -$4000.0 in the prior quarter.
The five-year high for Change in Account Payables was $664000.0 in Q2 2025, with the low at -$4000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Account Payables (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	-
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	-
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	-
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	-
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	571.00 Mn
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	-67.00 Mn
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	409.00 Mn
10	Nasus Pharma	23.47 Mn	19.18 Mn	-	-

Download Data